Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now
  • Home
  • Newsroom
  • News Releases
  • Dana-Farber awarded $6.5 million federal grant to study development of universal vaccine against influenza A

Dana-Farber awarded $6.5 million federal grant to study development of universal vaccine against influenza A

Six-center national consortium to study changes in human immune system

Ellis Reinherz, MD

Ellis Reinherz, MD

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a group of researchers at Dana-Farber Cancer Institute a $6.5 million, five-year grant to fund research focused on developing a universal vaccine against human influenza A viruses.

Ellis L. Reinherz, MD, faculty director of the Cancer Vaccine Center at Dana-Farber and a professor of medicine at Harvard Medical School, is the principal investigator for the Dana-Farber grant. The other Dana-Farber collaborators include Vladimir Brusic, PhD, Bruce Reinhold, PhD, Jonathan Duke-Cohan, PhD, Derin Keskin, PhD, and Guanglan Zhang, PhD.

"This grant will enable us to investigate a new approach in an effort to develop a T cell-based vaccine against human influenza A viruses," says Reinherz.

"Our ultimate goal is a vaccine that targets the conserved viral segments that cannot vary from one viral strain to another, thereby providing protection against all seasonal and pandemic flus. Such an advance will eliminate the need to alter the vaccine when there is a new global threat, as is necessary for current antibody-inducing approaches."

The grant is part of the NIAID's newly launched nationwide research initiative to define changes in the human immune system in response to infection or to vaccination.

Dana-Farber is one of six U.S.-based Human Immune Phenotyping Centers that collectively will receive a total of $100 million over five years to conduct this research.

The other centers are Baylor Research Institute, Dallas; Emory University, Atlanta; Mayo Clinic, Rochester, Minn.; Stanford University, Calif.; and Yale University, New Haven, Conn. Support for the first year of this initiative will come from the American Recovery and Reinvestment Act.

8/18/2017 4:09:46 PM
  •   Email
  •   Print
  •   Share
  • Media Contacts

    • For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online